- Home
- BST vs MDXG Comparison
BST vs MDXG Comparison
Compare BST & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BST | MDXG |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BST | MDXG |
|---|---|---|
| Price | $40.67 | $6.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 123.7K | ★ 838.9K |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | ★ 10.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $393,442,000.00 |
| Revenue This Year | N/A | $19.13 |
| Revenue Next Year | N/A | $2.11 |
| P/E Ratio | ★ N/A | $23.70 |
| Revenue Growth | N/A | ★ 14.77 |
| 52 Week Low | $27.87 | $5.79 |
| 52 Week High | $44.50 | $9.36 |
Technical Indicators
Market Signals| Indicator | BST | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 36.64 |
| Support Level | $39.87 | $6.25 |
| Resistance Level | $41.08 | $7.13 |
| Average True Range (ATR) | 0.66 | 0.22 |
| MACD | 0.09 | -0.07 |
| Stochastic Oscillator | 66.57 | 15.06 |
Price Performance
Historical ComparisonAbout BST BlackRock Science and Technology Trust of Beneficial Interest
BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objective is to provide income and total return through a combination of current income, current gains, and long-term capital appreciation. It focuses on investing, under a normal market condition in equity securities of science and technology companies.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.